Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17805170 | 0.85 | GAA (0.49) | GAARXRARXRBRXRGNPSR1 | |
| SCHEMBL39190 | 0.85 | GAA (0.66) | GAARXRARXRBRXRGNPSR1 | |
| Methane SCHEMBL2168088 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| Ammonia Solution, Strong SCHEMBL4047307 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| SCHEMBL31344084 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| Hydrochloric Acid SCHEMBL7945960 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| Ammonia Solution, Strong SCHEMBL1082127 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| SCHEMBL10554758 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| SCHEMBL11368092 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 | |
| Phosphine SCHEMBL28705181 | 0.84 | GAA (0.64) | GAARXRARXRBRXRGNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115117-A1 | NOVEL MACROMOLECULAR ANTIOXIDANTS COMPRISING DIFFERING ANTIOXIDANT MOIETIES: STRUCTURES, METHODS OF MAKING AND USING THE SAME | POLNOX CORPORATION | 2016-04-28 | — | — | US | disclosed |
| EP-2443192-B1 | Flame-retardant polyamide moulding materials | THOR GMBH (DE) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115117-A1 | NOVEL MACROMOLECULAR ANTIOXIDANTS COMPRISING DIFFERING ANTIOXIDANT MOIETIES: STRUCTURES, METHODS OF MAKING AND USING THE SAME | GPX4, GPX1, TXN2 | GAA 953/4885RXRA 1883/4885RXRB 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.